Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection: A Multicenter Prospective Study

NCT07077798 is registered in ClinicalTrials.gov with Wan-Guang Zhang as lead sponsor.

NCT NCT07077798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection: A Multicenter Prospective Study
Lead sponsor
Wan-Guang Zhang
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
December 31, 2027
Enrollment
234 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)